<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Richardson, P.G.</style></author><author><style face="normal" font="default" size="100%">Hungria, V.T.M.</style></author><author><style face="normal" font="default" size="100%">Yoon, S.-S.</style></author><author><style face="normal" font="default" size="100%">Beksac, M.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Elghandour, A.</style></author><author><style face="normal" font="default" size="100%">Jedrzejczak, W.W.</style></author><author><style face="normal" font="default" size="100%">Guenther, A.</style></author><author><style face="normal" font="default" size="100%">Na Nakorn, T.</style></author><author><style face="normal" font="default" size="100%">Siritanaratkul, N.</style></author><author><style face="normal" font="default" size="100%">Schlossman, R.L.</style></author><author><style face="normal" font="default" size="100%">Hou, J.</style></author><author><style face="normal" font="default" size="100%">Moreau, P.</style></author><author><style face="normal" font="default" size="100%">Lonial, S.</style></author><author><style face="normal" font="default" size="100%">Lee, J.H.</style></author><author><style face="normal" font="default" size="100%">Einsele, H.</style></author><author><style face="normal" font="default" size="100%">Sopala, M.</style></author><author><style face="normal" font="default" size="100%">Bengoudifa, B.-R.</style></author><author><style face="normal" font="default" size="100%">Corrado, C.</style></author><author><style face="normal" font="default" size="100%">Binlich, F.</style></author><author><style face="normal" font="default" size="100%">San-Miguel, J.F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959357825&amp;doi=10.1182%2fblood-2015-09-665018&amp;partnerID=40&amp;md5=b78bd086d16101d09f5bb27e5a444c69</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">127</style></volume><pages><style face="normal" font="default" size="100%">713 - 721</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significant increase in progression-free survival (PFS) vs placebo plus bortezomib and dexamethasone (Pbo-BTZ-Dex) in patients with relapsed or relapsed and refractoryMMin the phase 3PANORAMA1 trial. This subgroup analysis evaluated outcomes in patients in the PANORAMA 1 trial based on prior treatment: A prior immunomodulatory drug (IMiD; n 5 485), prior bortezomib plus an IMiD (n 5 193), and ≥2 prior regimens including bortezomib and an IMiD (n5147). Median PFS with PAN-BTZ-Dex vs Pbo-BTZ-Dex across subgroups was as follows: prior IMiD (12.3 vs 7.4 months; hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.43-0.68), prior bortezomib plus IMiD (10.6 vs 5.8 months; HR, 0.52;95%CI, 0.36-0.76),and ≥2 prior regimens including bortezomib and an IMiD (12.5 vs 4.7 months; HR, 0.47; 95% CI, 0.31-0.72). Common grade 3/4 adverse events and laboratory abnormalities in patients who received PAN-BTZ-Dex across the prior treatment groups included thrombocytopenia, lymphopenia, neutropenia, diarrhea, and asthenia/ fatigue. Incidence of on-treatment deaths among patients who received prior bortezomib and an IMiD (regardless of number of prior regimens) was similar between treatment arms. This analysis demonstrated a clear PFS benefit of 7.8 months with PAN-BTZ-Dex among patients who received ‡2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis. This trial was registered at www.clinicaltrials.gov as #NCT01023308. © 2016 by The American Society of Hematology.</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><notes><style face="normal" font="default" size="100%">Cited By :18Export Date: 21 February 2017</style></notes></record></records></xml>